npj Precision Oncology (Oct 2024)

The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCG

  • Qi-Dong Xia,
  • Jian-Xuan Sun,
  • Zhi-Peng Yao,
  • Jun-Lin Lu,
  • Chen-Qian Liu,
  • Jin-Zhou Xu,
  • Ye An,
  • Meng-Yao Xu,
  • Si-Han Zhang,
  • Xing-Yu Zhong,
  • Na Zeng,
  • Si-Yang Ma,
  • Hao-Dong He,
  • Heng-Long Hu,
  • Jia Hu,
  • Yi Lu,
  • Bing Li,
  • Yao-Bing Chen,
  • Zheng Liu,
  • Shao-Gang Wang

DOI
https://doi.org/10.1038/s41698-024-00725-4
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

Abstract We aimed to investigate the genomic and tumor microenvironmental (TME) profiles in non-muscle invasive bladder cancer (NMIBC) and explore potential predictive markers for Bacillus Calmette–Guérin (BCG) treatment response in high-risk NMIBC patients (according to European Association of Urology (EAU) risk stratification). 40 patients with high-risk NMIBC (cTis-T1N0M0) who underwent en bloc resection followed by BCG instillation were retrospectively enrolled. Surgical samples were subjected to Next Generation Sequencing (NGS) and multiplex immunofluorescence (mIF) assay. Genomic profiling revealed high prevalences of alterations in TERT (55%), KDM6A (32.5%), FGFR3(30%), PIK3CA (30%), TP53(27.5%) and ARID1A (20%). TME analysis showed different proportions of macrophages, NK cells, T cells subsets in tumoral and stromal compartment. Multivariate analysis identified TERT C228T and alteration in KDM6A as two independent factors associated with inferior RFS. The study comprehensively depicted the genomic and TME profiles in NMIBC and identified potential predictive biomarkers for BCG treatment.